Experimental combo for advanced cancers halted early
NCT ID NCT06438783
First seen Jan 09, 2026 · Last updated Jun 15, 2026 · Updated 21 times
Summary
This early-stage trial tested a combination of two drugs (TQB2928 and anlotinib) in 20 people with advanced bone cancer (osteosarcoma) or other solid tumors that had come back or spread. The goal was to see if the combo could shrink tumors or delay cancer growth. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing cancer hospital
Beijing, Beijing Municipality, 100142, China
-
Beijing jishuitan hospital
Beijing, Beijing Municipality, 100035, China
-
Hunan cancer hospital
Changsha, Hunan, 410031, China
-
Pekjing university people's hospital
Beijing, Beijing Municipality, 100044, China
-
Tianjin medical university cancer institute&hospital
Tianjin, Tianjin Municipality, 300181, China
Conditions
Explore the condition pages connected to this study.